| scholarly article | Q13442814 |
| P50 | author | Irene Ghobrial | Q88032966 |
| Kalvis Hornburg | Q88246173 | ||
| P2093 | author name string | Michael Martin | |
| Kenneth C Anderson | |||
| Paul G Richardson | |||
| Jacalyn Rosenblatt | |||
| Chia-Jen Liu | |||
| Jacob P Laubach | |||
| Stacey Chuma | |||
| Kenneth H Shain | |||
| Andrew J Yee | |||
| Philippe Armand | |||
| Robert L Schlossman | |||
| Bradley Rivotto | |||
| Noopur S Raje | |||
| Craig Reynolds | |||
| Stew Kroll | |||
| Damian R Handisides | |||
| Alexandra Savell | |||
| Laura Stampleman | |||
| Henry J Dumke | |||
| Ira Zackon | |||
| Jacquelyn Hedlund | |||
| Patrick Henrick | |||
| P2860 | cites work | Hallmarks of Cancer: The Next Generation | Q22252312 |
| Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma | Q27853189 | ||
| Microenvironmental regulation of tumor progression and metastasis | Q29615504 | ||
| Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study | Q33400424 | ||
| Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma | Q33417472 | ||
| Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma | Q33431778 | ||
| Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma | Q33435789 | ||
| Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study | Q33942495 | ||
| Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302. | Q34238898 | ||
| Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy | Q34263870 | ||
| International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma | Q34450381 | ||
| First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies | Q34501199 | ||
| Genomic complexity of multiple myeloma and its clinical implications | Q34537571 | ||
| International uniform response criteria for multiple myeloma. | Q34549410 | ||
| Role of hypoxia and glycolysis in the development of multi-drug resistance in human tumor cells and the establishment of an orthotopic multi-drug resistant tumor model in nude mice using hypoxic pre-conditioning | Q34610733 | ||
| Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs. | Q34747300 | ||
| Hypoxia-induced Jagged2 promotes breast cancer metastasis and self-renewal of cancer stem-like cells | Q35134466 | ||
| Hypoxia-inducible factor 1 is a master regulator of breast cancer metastatic niche formation | Q35239845 | ||
| Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features | Q36057606 | ||
| Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets | Q36889961 | ||
| Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer | Q36938779 | ||
| TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules. | Q37700855 | ||
| Role of endothelial progenitor cells in cancer progression | Q38202716 | ||
| Targeting the bone marrow microenvironment in multiple myeloma. | Q38289041 | ||
| International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma | Q38832525 | ||
| Hypoxia promotes dissemination and colonization in new bone marrow niches in Waldenström macroglobulinemia | Q38955445 | ||
| Synergistic induction of apoptosis in multiple myeloma cells by bortezomib and hypoxia-activated prodrug TH-302, in vivo and in vitro. | Q39129256 | ||
| Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer. | Q39425368 | ||
| Targeting angiogenesis via a c-Myc/hypoxia-inducible factor-1alpha-dependent pathway in multiple myeloma | Q39840627 | ||
| Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma | Q41700620 | ||
| Hypoxia signaling--license to metastasize | Q41866894 | ||
| Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of TH-302, a Hypoxia-Activated Prodrug, in Patients with Advanced Solid Malignancies | Q42745781 | ||
| Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug | Q45851460 | ||
| Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond | Q47283493 | ||
| NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018. | Q47561787 | ||
| The bone-marrow niche in MDS and MGUS: implications for AML and MM. | Q50114615 | ||
| Safety Outcomes for Autologous Stem Cell Transplant in Multiple Myeloma | Q50163135 | ||
| Targeting vasculogenesis to prevent progression in multiple myeloma | Q52885536 | ||
| Low bone marrow oxygen tension and hypoxia-inducible factor-1α overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138+ cells | Q60197167 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hypoxia | Q105688 |
| P304 | page(s) | 478-486 | |
| P577 | publication date | 2018-10-02 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma | |
| P478 | volume | 25 |
Search more.